X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Through the divestment, the company has acquired the rights and will concentrate on commercializing Loxacin (loxapine succinate) for treating psychotic disorders and personality disorders.
Lead Product(s): Loxapine Succinate
Therapeutic Area: Psychiatry/Psychology Product Name: Loxapac
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: CNX Therapeutics
Deal Size: $61.3 million Upfront Cash: Undisclosed
Deal Type: Divestment April 02, 2024
Details:
Leqembi (lecanemab-irmb) is a humanized immunoglobulin gamma 1 (IgG1) monoclonal antibody directed against aggregated soluble (protofibril) and insoluble forms of amyloid-beta (Aβ). It is being evaluated as IV maintenance dosing for the treatment of early Alzheimer's disease.
Lead Product(s): Lecanemab
Therapeutic Area: Neurology Product Name: Leqembi
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: BioArctic AB
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 31, 2024
Details:
Eisai divested its rights for vertigo and equilibrium disturbance treatment Merislon (betahistine mesilate), used to treat Meniere's syndrome, and muscle relaxant Myonal (eperisone hydrochloride) in Japan to Kaken.
Lead Product(s): Betahistine Dimesilate
Therapeutic Area: Otolaryngology (Ear, Nose, Throat) Product Name: Merislon
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Kaken Pharmaceuticals
Deal Size: $25.0 million Upfront Cash: Undisclosed
Deal Type: Divestment March 29, 2024
Details:
Metoject subcutaneous injection pen (methotrexate) works by inhibiting dihydrofolic acid reductase enzyme. It is approved for the treatment of rheumatoid arthritis.
Lead Product(s): Methotrexate
Therapeutic Area: Immunology Product Name: Metoject
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Nippon Medac
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 15, 2024
Details:
Lymphir (denileukin diftitox) is a recombinant fusion protein that combines the interleukin-2 (IL-2) receptor binding domain with diphtheria toxin fragments. It is being developed for the treatment of adults with relapsed or refractory cutaneous T-cell lymphoma.
Lead Product(s): Denileukin Diftitox
Therapeutic Area: Oncology Product Name: Lymphir
Highest Development Status: Phase IIIProduct Type: Large molecule
Recipient: Citius Pharmaceuticals
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 14, 2024
Details:
Methycobal (methylcobalamin) is the active form of vitamin B12. It is indicated for the treatment of peripheral neuropathies and megaloblastic anemia caused by vitamin B12 deficiency.
Lead Product(s): Methylcobalamin
Therapeutic Area: Neurology Product Name: Methycobal
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 26, 2024
Details:
Fycompa® (perampanel) is a highly selective, non-competitive AMPA glutamate receptor antagonist. It is indicated for the treatment of partial-onset seizures & primary generalized tonic-clonic seizures in patients with epilepsy 12 years of age and older.
Lead Product(s): Perampanel
Therapeutic Area: Neurology Product Name: Fycompa
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 18, 2024
Details:
Leqembi (lecanemab-irmb) is a humanized immunoglobulin gamma 1 (IgG1) monoclonal antibody directed against aggregated soluble (protofibril) and insoluble forms of amyloid-beta (Aβ). It is indicated for the treatment of Alzheimer’s disease.
Lead Product(s): Lecanemab-irmb
Therapeutic Area: Neurology Product Name: Leqembi
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Biogen
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 11, 2024
Details:
E7090 (tasurgratinib succinate) is a small molecule, FGFR 1/2/3 inhibitor which is under phase 2 clinical development for the treatment of biliary tract cancer WITH fgfr2 gene fusion.
Lead Product(s): Tasurgratinib Succinate
Therapeutic Area: Oncology Product Name: E7090
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 18, 2023
Details:
The financing will be used to develop a radical cure for P. vivax malaria. SJ000557733 (SJ733), an antimalarial drug candidate, has completed a Phase IIa trial for single administration and has shown efficacy and tolerability against P. vivax malaria.
Lead Product(s): SJ733
Therapeutic Area: Infections and Infectious Diseases Product Name: SJ000557733
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: GHIT Fund
Deal Size: $5.4 million Upfront Cash: Undisclosed
Deal Type: Financing December 13, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
